Aprea Therapeutics, Inc. (APRE) Form 8-K — May 13, 2026
Aprea Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026, with cash and cash equivalents increasing to $46.5 million from $14.6 million as of December 31, 2025. The company also announced a net loss of $3.3 million, or $0.22 per share, for the quarter, compared to a net loss of $3.9 million, or $0.66 per share, in the same period last year. The company observed two partial responses in the ongoing Phase 1 dose escalation ACESOT-1051 trial of WEE1 inhibitor APR-1051.
Key figures
- Eps
- -0.22
- Net Income
- -3,287,917
- Cash Position
- 46,466,202
- Gross Proceeds
- 30,000,000
- Shares Outstanding
- 11,982,776
Price after filing
Close on the filing date to close N calendar days later (from $0.88). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.